BOSTON--(BUSINESS WIRE)--GRO Biosciences Inc. (“GRObio”), an emerging biotechnology company leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics, today announced that it will...
Read More
BOSTON--(BUSINESS WIRE)--GRO Biosciences Inc. (“GRObio”), an emerging biotechnology company leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics, today announced the appointment of...
Read More
Therapeutic proteins are used to treat a wide variety of diseases, from cancer and heart disease to cystic fibrosis and diabetes. These proteins currently are produced using microbial fermentation in...
Read More
GRO Biosciences tackles ‘Holy Grail’ challenges, using non-standard amino acids to expand the amino acid palette Last month, GRObio completed a $25-million Series A financing co-led by Leaps by Bayer...
Read More
BOSTON--(BUSINESS WIRE)--GRO Biosciences Inc. (“GRObio”), an emerging biotechnology company leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics, today announced the appointment of...
Read More
November 16, 2021 06:55 AM Eastern Standard Time BOSTON--(BUSINESS WIRE)--GRO Biosciences Inc. (“GRObio”), an emerging biotechnology company leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise...
Read More
Six years ago, Daniel Mandell appeared on NPR to talk about an invention out of Jurassic Park. As Crichton and Goldblum fans recall, International Genetic Technologies, Inc.’s contingency plan to...
Read More
BOSTON, November 3, 2021 – GRO Biosciences Inc. (“GRObio”), an emerging biotechnology company leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics, today announced the closing of a Series A financing
GRO Biosciences Inc. wants to make a giant sector in the pharmaceutical industry even larger. The spinout from the lab of Harvard Medical School geneticist George Church aims to make protein drugs more versatile and effective
